Fatty Acid Signaling Impacts Prostate Cancer Lineage Plasticity in an Autocrine and Paracrine Manner.
Wnt
androgen
cancer associated fibroblast
cholesterol
free fatty acid
hedgehog
prostate cancer
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
15 Jul 2022
15 Jul 2022
Historique:
received:
09
06
2022
revised:
30
06
2022
accepted:
11
07
2022
entrez:
27
7
2022
pubmed:
28
7
2022
medline:
28
7
2022
Statut:
epublish
Résumé
Prostate cancer (PCa) affects an estimated 250,000 men every year and causes 34,000 deaths annually. A high-fat diet and obesity are associated with PCa progression and mortality. This study's premise was the novel observation of crosstalk between PCa epithelia and cancer-associated fibroblasts (CAF) in response to palmitate-mediated lineage plasticity. We found that cholesterol activated canonical Hedgehog (Hh) signaling by increasing cilium Gli activity in PCa cells, while palmitate activated Hh independent of Gli. Exogenous palmitate activated SOX2, a known mediator of lineage plasticity, in PCa cells cocultured with CAF. Stroma-derived Wnt5a was upregulated in CAF while cocultured with PCa cells and treated with palmitate. Wnt5a knockdown in CAF inhibited Hh and SOX2 expression in PCa cells from cocultures. These findings supported our proposed mechanism of a high-fat diet promoting Hh signaling-mediated transformation within the tumor microenvironment. SOX2 and Wnt5a expression were limited by the CD36 neutralizing antibody. Mice xenografted with PCa epithelia and CAF tumors were fed a high-fat diet, leading to elevated SOX2 expression and lineage plasticity reprogramming compared to mice fed an isocaloric rodent diet. CD36 inhibition with enzalutamide elevated apoptosis by TUNEL, but limited proliferation and SOX2 expression compared to enzalutamide alone. This study revealed a mechanism for a high-fat diet to affect prostate cancer progression. We found that saturated fat induced lineage plasticity reprogramming of PCa by interaction with CAF through Wnt5a and Hh signaling.
Identifiants
pubmed: 35884514
pii: cancers14143449
doi: 10.3390/cancers14143449
pmc: PMC9318639
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : NCI NIH HHS
ID : P01 CA233452
Pays : United States
Organisme : Veteran Health Administration Merit Award
ID : I01BX001040
Organisme : United States Department of Defense
ID : W81XWH-18-1-0252
Organisme : NCI NIH HHS
ID : CA233452
Pays : United States
Références
Prostate. 2006 Nov 1;66(15):1664-73
pubmed: 16902972
Cancers (Basel). 2015 Aug 11;7(3):1554-85
pubmed: 26270676
Lancet Oncol. 2019 Oct;20(10):1338-1340
pubmed: 31515155
Cell Adh Migr. 2012 May-Jun;6(3):231-5
pubmed: 22568983
Cancer Cell. 2013 Mar 18;23(3):332-46
pubmed: 23518348
Endocrinology. 1988 Feb;122(2):552-62
pubmed: 2828003
Nat Rev Urol. 2018 May;15(5):271-286
pubmed: 29460922
Cancer Cell. 2017 Dec 11;32(6):792-806.e7
pubmed: 29153843
Mol Cancer Res. 2016 Apr;14(4):374-84
pubmed: 26753621
Mol Cancer. 2004 Oct 13;3:29
pubmed: 15482598
Int J Mol Sci. 2014 Dec 26;16(1):378-400
pubmed: 25548896
Nature. 2004 Oct 7;431(7009):707-12
pubmed: 15361885
Sci Transl Med. 2019 Feb 6;11(478):
pubmed: 30728288
Pathology. 1984 Oct;16(4):406-10
pubmed: 6522105
Oncogene. 2018 Aug;37(32):4385-4397
pubmed: 29717261
Int J Mol Sci. 2013 Jul 04;14(7):13979-4007
pubmed: 23880852
Nutrients. 2014 Dec 22;6(12):6095-109
pubmed: 25533015
Prostate. 1984;5(5):545-57
pubmed: 6483690
Virchows Arch B Cell Pathol. 1973 Jun 25;13(2):87-102
pubmed: 4201202
Oncogene. 2014 Oct 9;33(41):4924-31
pubmed: 24141771
Nature. 2004 Nov 18;432(7015):332-7
pubmed: 15549095
Clin Cancer Res. 2003 Oct 15;9(13):4792-801
pubmed: 14581350
Cancer Med. 2019 Oct;8(14):6370-6382
pubmed: 31468733
Oncogene. 2010 Apr 8;29(14):2036-46
pubmed: 20101234
Oncogene. 2019 Jan;38(5):716-730
pubmed: 30177832
Oncogene. 2018 Apr;37(17):2313-2325
pubmed: 29429990
Cells. 2020 Jan 03;9(1):
pubmed: 31947770
Cancer Res. 1999 Oct 1;59(19):5002-11
pubmed: 10519415
Cancer Res. 2001 Nov 15;61(22):8135-42
pubmed: 11719442
Cancer Res. 2008 Jul 15;68(14):5785-94
pubmed: 18632632
Clin Cancer Res. 2010 Jun 15;16(12):3130-40
pubmed: 20530699
J Clin Med. 2019 Apr 30;8(5):
pubmed: 31052319
Cancer Res. 2011 Jul 15;71(14):4989-97
pubmed: 21632551
Cancer Res. 2010 Apr 15;70(8):3382-90
pubmed: 20395211
Cancer Res. 2008 Jun 15;68(12):4709-18
pubmed: 18559517
PLoS One. 2012;7(1):e30062
pubmed: 22279565
Biochim Biophys Acta Mol Basis Dis. 2017 Jan;1863(1):253-265
pubmed: 27816521
Ther Adv Med Oncol. 2010 Jul;2(4):237-50
pubmed: 21789137
Science. 2017 Jan 6;355(6320):84-88
pubmed: 28059768
Br J Cancer. 2020 Jan;122(1):4-22
pubmed: 31819192
Science. 2004 Feb 6;303(5659):848-51
pubmed: 14764882
Cancer Res. 2011 May 15;71(10):3459-70
pubmed: 21444670
J Hematol Oncol. 2019 Aug 28;12(1):86
pubmed: 31462327
Eur Urol. 2020 Jan;77(1):38-52
pubmed: 31493960
J Clin Invest. 2018 Oct 1;128(10):4472-4484
pubmed: 30047926
Cancers (Basel). 2020 Oct 24;12(11):
pubmed: 33114328
J Clin Oncol. 2004 Feb 1;22(3):439-45
pubmed: 14691120
Clin Cancer Res. 2005 Oct 1;11(19 Pt 1):6763-6
pubmed: 16203761
Front Immunol. 2021 Jul 08;12:671595
pubmed: 34305902
Int J Epidemiol. 2020 Jun 1;49(3):810-823
pubmed: 32016289
Nat Rev Cancer. 2020 Mar;20(3):174-186
pubmed: 31980749
Curr Opin Pharmacol. 2012 Dec;12(6):736-41
pubmed: 22832232
Oncogene. 2022 Feb;41(8):1190-1202
pubmed: 35067686
Nutrients. 2019 Oct 25;11(11):
pubmed: 31731503
Curr Opin Pharmacol. 2012 Dec;12(6):751-9
pubmed: 22824430
Int J Mol Sci. 2021 Jun 10;22(12):
pubmed: 34200820
Nature. 2017 Jan 5;541(7635):41-45
pubmed: 27974793
Gut. 2020 Feb;69(2):243-251
pubmed: 31085554
J Exp Med. 2019 Feb 4;216(2):428-449
pubmed: 30593464
Oncogene. 2008 Nov 27;27(56):7118-30
pubmed: 18724388
Diabetes Obes Metab. 2021 Nov;23(11):2455-2465
pubmed: 34212475
Nat Commun. 2019 Sep 25;10(1):4358
pubmed: 31554818
Br J Cancer. 2018 Mar 6;118(5):670-678
pubmed: 29381686
Nat Commun. 2016 Aug 05;7:12321
pubmed: 27492255
Nat Chem Biol. 2020 Dec;16(12):1303-1313
pubmed: 33199907
Molecules. 2015 Sep 18;20(9):17339-61
pubmed: 26393565
BMC Biol. 2017 Oct 26;15(1):95
pubmed: 29073896
Nat Rev Cancer. 2020 Feb;20(2):74-88
pubmed: 31686003
Mol Cancer Res. 2018 Apr;16(4):643-654
pubmed: 29453313
Gut. 2020 Apr;69(4):630-640
pubmed: 31409603
Prostate. 2019 Jun;79(8):896-908
pubmed: 30900312
Transl Androl Urol. 2019 Jul;8(Suppl 3):S348-S350
pubmed: 31392166
Cancers (Basel). 2020 Jul 13;12(7):
pubmed: 32668821